-
1.发明授权Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules 有权由SSX或NY-ESO-1分子中发现的与HLA分子结合的氨基酸序列组成的分离的肽公开(公告)号：US06548064B1
公开(公告)日：2003-04-15
申请号：US09344040
申请日：1999-06-25
IPC分类号： A61K3900
摘要： The invention relates to members of the SSX family of genes, as well as their uses. Also a part of the invention are peptides derived from SSX molecules and the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T cells.
摘要翻译： 本发明涉及SSX家族基因的成员及其用途。 本发明的一部分也是衍生自SSX分子和NY-ESO-1分子的肽，其与HLA分子形成复合物，导致细胞溶解性T细胞裂解呈现这些复合物的细胞。
-
2.发明授权Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof 有权编码分离的肽的分离的核酸分子，其对应于SSX分子或NY-ESO-1的连续氨基酸并且其用途公开(公告)号：US07270819B2
公开(公告)日：2007-09-18
申请号：US10177277
申请日：2002-06-21
摘要： The invention relates to members of the SSX family of genes, as well as their uses. Also a part of the invention are peptides derived from SSX molecules and the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T cells.
摘要翻译： 本发明涉及SSX家族基因的成员及其用途。 本发明的一部分也是衍生自SSX分子和NY-ESO-1分子的肽，其与HLA分子形成复合物，导致细胞溶解性T细胞裂解呈现这些复合物的细胞。
-
公开(公告)号：US07528224B1
公开(公告)日：2009-05-05
申请号：US11414897
申请日：2006-05-01
CPC分类号： C07K14/4727 , A61K39/00 , A61K48/00 , A61K2039/53
摘要： The invention relates to a peptide for triggering an immune response to tumor cells. Said peptide has an optionally modified fragment of the protein that is encoded by the gene MUC-1. Said protein triggers an HLA-A2-restricted immune response.
摘要翻译： 本发明涉及一种用于触发对肿瘤细胞免疫应答的肽。 所述肽具有由基因MUC-1编码的蛋白质的任选修饰的片段。 所述蛋白质触发HLA-A2限制性免疫应答。
-
4.发明授权HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof 有权衍生自前列腺相关抗原分子的HLA结合肽及其使用方法公开(公告)号：US09023802B2
公开(公告)日：2015-05-05
申请号：US12967606
申请日：2010-12-14
申请人： Hans Georg Rammensee , Stefan Stevanovic , Cecile Gouttefangeas , Toni Weinschenk , Peter Lewandrowski
发明人： Hans Georg Rammensee , Stefan Stevanovic , Cecile Gouttefangeas , Toni Weinschenk , Peter Lewandrowski
CPC分类号： C07K14/4748 , A61K39/0011 , A61K2039/55566
摘要： Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. Patients are treated with compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants.
摘要翻译： 公开了用于前列腺癌免疫治疗的方法和组合物。 用包含或不含免疫佐剂的来自前列腺相关抗原分子的HLA结合肽的组合物治疗患者。
-
公开(公告)号：US08536304B2
公开(公告)日：2013-09-17
申请号：US12632541
申请日：2010-01-22
IPC分类号： C07K7/06
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
摘要： The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
摘要翻译： 本发明涉及含有氨基酸序列的肿瘤相关肽，其选自所附列举的SEQ ID NO：1至SEQ ID NO：79。 该肽具有结合人类主要组织相容性复合体（MHC）I类分子的能力。 本发明还涉及肽用于制备药物和治疗肿瘤疾病的用途。 本发明还涉及包含至少一种肽的药物组合物。
-
公开(公告)号：US08399613B2
公开(公告)日：2013-03-19
申请号：US12632463
申请日：2010-01-22
IPC分类号： C07K7/06
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
摘要： The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
-
7.发明申请HLA-BINDING PEPTIDES DERIVED FROM PROSTATE-ASSOCIATED ANTIGENIC MOLECULES AND METHODS OF USE THEREOF 有权从前列腺相关抗原分子衍生的HLA结合肽及其使用方法公开(公告)号：US20120082691A1
公开(公告)日：2012-04-05
申请号：US12967606
申请日：2010-12-14
申请人： Hans Georg Rammensee , Stefan Stevanovic , Cecile Gouttefangeas , Toni Weinschenk , Peter Lewandrowski
发明人： Hans Georg Rammensee , Stefan Stevanovic , Cecile Gouttefangeas , Toni Weinschenk , Peter Lewandrowski
CPC分类号： C07K14/4748 , A61K39/0011 , A61K2039/55566
摘要： Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. Patients are treated with compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants.
摘要翻译： 公开了用于前列腺癌免疫治疗的方法和组合物。 用包含或不含免疫佐剂的来自前列腺相关抗原分子的HLA结合肽的组合物治疗患者。
-
公开(公告)号：US20090221509A1
公开(公告)日：2009-09-03
申请号：US10549718
申请日：2004-03-23
申请人： Hans Georg Rammensee , Stefan Stevanovic , Toni Weinschenk , Claudia Lemmel , Jörg Dengjel , Oliver Schoor
发明人： Hans Georg Rammensee , Stefan Stevanovic , Toni Weinschenk , Claudia Lemmel , Jörg Dengjel , Oliver Schoor
IPC分类号： A61K38/10 , A61K35/12 , C12N5/10 , C12N15/63 , G01N33/68 , A61K38/08 , C07K7/08 , C07K7/06 , C07H21/00
CPC分类号： C07K7/06 , A61K38/00 , C07K14/47 , C07K14/4748 , C07K14/78
摘要： The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID-No. 1 to SEQ ID-No. 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC) class-I. In addition, the invention relates to the use of the peptides and the nucleic acids encoding for the peptides for the production of a medicament, and for the treatment of tumorous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that has at least one of the peptides.
摘要翻译： 本发明涉及具有选自SEQ ID NO：1的氨基酸序列的肿瘤相关肽。 1至SEQ ID No。 101，其中肽具有结合人类主要组织相容性复合物（MHC）I类分子的能力。 此外，本发明涉及肽和编码肽的核酸用于制备药物以及用于治疗肿瘤疾病和/或腺瘤性疾病的用途。 此外，描述了具有至少一种肽的药物组合物。
-
公开(公告)号：US07396904B2
公开(公告)日：2008-07-08
申请号：US10999364
申请日：2004-11-29
IPC分类号： C07K16/00
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
摘要： The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
摘要翻译： 本发明涉及含有氨基酸序列的肿瘤相关肽，其选自所附列举的SEQ ID NO：1至SEQ ID NO：79。 该肽具有结合人类主要组织相容性复合体（MHC）I类分子的能力。 本发明还涉及肽用于制备药物和治疗肿瘤疾病的用途。 本发明还涉及包含至少一种肽的药物组合物。
-
10.发明授权HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof 有权衍生自前列腺相关抗原分子的HLA结合肽及其使用方法公开(公告)号：US09023804B2
公开(公告)日：2015-05-05
申请号：US13993291
申请日：2011-11-14
申请人： Toni Weinschenk , Peter Lewandrowski , Hans Georg Rammensee , Stefan Stevanovic , Cecile Gouttefangeas
发明人： Toni Weinschenk , Peter Lewandrowski , Hans Georg Rammensee , Stefan Stevanovic , Cecile Gouttefangeas
CPC分类号： A61K39/0011 , A61K38/00 , A61K45/06 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55566 , C12N9/6445
摘要： Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed.
摘要翻译： 公开了用于前列腺癌免疫治疗的方法和组合物。 更具体地说，治疗患有前列腺癌的患者的方法包括施用组合物，其包含衍生自前列腺相关抗原性分子的HLA结合肽，含或不含免疫佐剂。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.031 秒)
